FRA:88Q - GB00BMCLYF79 - Common Stock
The current stock price of 88Q.DE is 9.7 EUR. In the past month the price decreased by -13.39%. In the past year, price decreased by -43.93%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20 | 319.75B | ||
1ABBV.MI | ABBVIE INC | 19.65 | 314.09B | ||
AMG.DE | AMGEN INC | 12.91 | 129.61B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.83 | 121.80B | ||
GIS.DE | GILEAD SCIENCES INC | 14.81 | 121.61B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.41 | 86.90B | ||
ARGX.BR | ARGENX SE | 86.58 | 39.16B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 23.37B | ||
IDP.DE | BIOGEN INC | 8.88 | 17.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.26B | ||
0QF.DE | MODERNA INC | N/A | 8.25B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The firm offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. The company utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The firm offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
4BASEBIO PLC
25 Norman Way, Over
CAMBRIDGE GB
Employees: 0
Phone: 441223967943
The current stock price of 88Q.DE is 9.7 EUR.
The exchange symbol of 4BASEBIO PLC is 88Q and it is listed on the Deutsche Boerse Ag exchange.
88Q.DE stock is listed on the Deutsche Boerse Ag exchange.
9 analysts have analysed 88Q.DE and the average price target is 19.3 EUR. This implies a price increase of 98.96% is expected in the next year compared to the current price of 9.7. Check the 4BASEBIO PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
4BASEBIO PLC (88Q.DE) has a market capitalization of 150.74M EUR. This makes 88Q.DE a Micro Cap stock.
4BASEBIO PLC (88Q.DE) currently has 0 employees.
4BASEBIO PLC (88Q.DE) has a support level at 9.69 and a resistance level at 10.99. Check the full technical report for a detailed analysis of 88Q.DE support and resistance levels.
The Revenue of 4BASEBIO PLC (88Q.DE) is expected to grow by 129.21% in the next year. Check the estimates tab for more information on the 88Q.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
88Q.DE does not pay a dividend.
4BASEBIO PLC (88Q.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE. 88Q.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months 88Q.DE reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS decreased by -51.13% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.57% | ||
ROE | -46.75% | ||
Debt/Equity | 0.57 |
9 analysts have analysed 88Q.DE and the average price target is 19.3 EUR. This implies a price increase of 98.96% is expected in the next year compared to the current price of 9.7.
For the next year, analysts expect an EPS growth of -7.86% and a revenue growth 129.21% for 88Q.DE